CHRONIC ATYPICAL NEUROLEPTIC TREATMENT IN NORMALLY DEVELOPING MACACA NEMESTRINA

正常发育的猕猴的慢性非典型神经抑制治疗

• 批准号: 7349322
• 负责人: GENE P. SACKETT
• 金额: $ 13.2万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349322
• 关键词: CHRONIC; ATYPICAL; NEUROLEPTIC; TREATMENT; NORMALLY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Atypical neuroleptic drugs are being used frequently in children and adolescents with severe psychopathology. The effects of these agents on normal growth and development are unknown. This 5-year project treats normally developing non-human primates (macaque nemestrina) with risperidone, quetiapine, or placebo from 13-20 months of age, followed by a 4 month post-drug period. 12 males will receive a low dose of risperidone or quetiapine for 4 months, then switched to a high dose for 4 months. 24 males will be assigned to the placebo condition. Animals are being tested before, during, and after drug or placebo treatment for (1) social, emotional, exploratory, learning and memory, motor skill, and perceptual behavior; and (2) physical assessments of health, somatic growth, bone mineralization, and hormonal function. The study design permits both between-group and within-individual comparisons to examine drug group differences as well as dose effects. Since m. nemestrina monkeys demonstrate psychological and somatic development comparable to humans, this project will identify aspects of human development that are likely to be affected by chronic treatment with these agents. 12-20 monkeys will be studied each year, with 20 currently being tested.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。非典型抗精神病药经常用于患有严重精神病理学的儿童和青少年。这些药物对正常生长和发育的影响尚不清楚。这个为期 5 年的项目使用利培酮、喹硫平或安慰剂治疗正常发育的非人类灵长类动物（猕猴 nemestrina），从 13 至 20 个月大，然后是 4 个月的药物后期。 12 名男性将接受低剂量利培酮或喹硫平治疗 4 个月，然后改用高剂量治疗 4 个月。 24 名男性将被分配到安慰剂组。在药物或安慰剂治疗之前、期间和之后对动物进行以下测试：（1）社交、情感、探索、学习和记忆、运动技能和知觉行为； (2) 健康、躯体生长、骨矿化和激素功能的身体评估。研究设计允许进行组间和个体内比较，以检查药物组差异以及剂量效应。自从米。 Nemestrina 猴表现出与人类相当的心理和躯体发育，该项目将确定可能受到这些药物长期治疗影响的人类发育的各个方面。每年将对 12-20 只猴子进行研究，目前有 20 只正在接受测试。